Sep 15, 2011 by Brian Orelli, PhDStop Worrying About Pfizer's BreakupSometimes you just have to trust management.
Sep 14, 2011 by Brian Orelli, PhDHow to Muck Up a Turnaround in 12 and a Half MonthsBoston Scientific Makes a Slow Transition to Its New CEO
Sep 13, 2011 by Brian Orelli, PhDDrug Launches: It's All About ExpectationsOptimer jumps on measly sales.
Sep 12, 2011 by Brian Orelli, PhDIs Dendreon a Turnaround Candidate?Or will the company's struggle continue?
Sep 9, 2011 by Brian Orelli, PhDFiring Squad, It Was NotJ&J and Bayer get through their advisory panel with minimal problems.
Sep 8, 2011 by Brian Orelli, PhDDelayed Data Coming Soon? EXELent!Exelixis should have data on cabozantinib early in the fourth quarter.
Sep 8, 2011 by Brian Orelli, PhDAll Approvals Are Not Created EqualMELA's EU approval isn't nearly as important as one stateside.
Sep 7, 2011 by Brian Orelli, PhDJ&J and Bayer Head in Front of the Firing SquadAn expanded indication for Xarelto seems unlikely.
Sep 6, 2011 by Brian Orelli, PhDBetter Late Than Never? Maybe.Can Vertex's rheumatoid arthritis drug, VX-509, succeed this late in the game?
Sep 2, 2011 by Brian Orelli, PhDDelcath Wants a Do-OverMixed results are often the most worrisome for investors.
Aug 31, 2011 by Brian Orelli, PhD3 Biotechs Ready to MoveThese companies could be poised for higher values.
Aug 31, 2011 by Brian Orelli, PhDAntibodies: They're Not Just for Fighting Infection AnymoreThe drugs continue to evolve.
Aug 31, 2011 by Brian Orelli, PhDThese Sales Matter MostSales ramp vs. peak sales: the valuation debate.
Aug 30, 2011 by Brian Orelli, PhDForget T-bills, Buy These Pharma Dividend Stocks InsteadFor the long term, they look like real winners.
Aug 30, 2011 by Brian Orelli, PhDAeterna Zentaris Passes Its TestAEZS-130, its diagnostic test for adult growth hormone deficiency, looks good.
Aug 29, 2011 by Brian Orelli, PhDA Less Painful FDA DecisionJohnson & Johnson gains approval of Nucynta ER.
